Back to Archived Journals » Biosimilars » Volume 6

Development, safety, and efficacy of biosimilar adalimumab: the data so far

Authors Gabbani T, Deiana S, Bagnoli S, Annese V

Received 30 July 2015

Accepted for publication 18 November 2015

Published 29 January 2016 Volume 2016:6 Pages 1—7

DOI https://doi.org/10.2147/BS.S55900

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lin Zhang

Peer reviewer comments 3

Editor who approved publication: Professor Shein-Chung Chow


Tommaso Gabbani, Simona Deiana, Siro Bagnoli, Vito Annese
 
Emergency Department, Division of Gastroenterology 2, AOU Careggi University Hospital, Florence, Italy

Abstract: Biologics are defined as active substances derived from living cells or organisms with the aid of biotechnology methods. A similar biological medicinal product, commonly referred to as a biosimilar, is a copy version of an approved original biological medicine whose data protection has expired. The main advantage of biosimilars is to lower prices and create financial savings for health care systems. Adalimumab (Humira) is a human recombinant monoclonal antibody against tumor necrosis factor-α, licensed for the treatment of several rheumatologic diseases and inflammatory bowel diseases. The original biologic agent has worldwide sales of approximately 12.5 billion US dollars, but the patent will expire in 2016 for the US and in 2018 for Europe. Adalimumab biosimilar is already currently marketed and used in a clinical setting in India, but many other companies are testing adalimumab biosimilars in order to request authorization from the European Medicines Agency and the US Food and Drug Administration at the time of patent expiry. In this gold rush, the long-term safety and immunogenicity of these drugs are an issue, but the striking rise of pharmaceutical expenses makes these drugs highly attractive for health care systems and pharmaceutical companies.

Keywords: adalimumab, IBD, biosimilar, biologics, Crohn's disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]